Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Profit After Tax (2022 - 2026)

Centessa Pharmaceuticals has reported Profit After Tax over the past 4 years, most recently at -$66.2 million for Q4 2025.

  • Quarterly Profit After Tax rose 40.57% to -$66.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$197.5 million through Dec 2025, up 16.21% year-over-year, with the annual reading at -$197.5 million for FY2025, 16.21% up from the prior year.
  • Profit After Tax was -$66.2 million for Q4 2025 at Centessa Pharmaceuticals, down from -$54.9 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$24.9 million in Q2 2023 and troughed at -$111.3 million in Q4 2024.
  • The 4-year median for Profit After Tax is -$47.1 million (2024), against an average of -$50.0 million.
  • Year-over-year, Profit After Tax skyrocketed 61.51% in 2023 and then crashed 202.22% in 2024.
  • A 4-year view of Profit After Tax shows it stood at -$43.2 million in 2022, then grew by 14.68% to -$36.8 million in 2023, then crashed by 202.22% to -$111.3 million in 2024, then surged by 40.57% to -$66.2 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Profit After Tax are -$66.2 million (Q4 2025), -$54.9 million (Q3 2025), and -$50.3 million (Q2 2025).